Table 1.
Patient baseline characteristics
|
| ||||||
| Monotherapy ( N = 137) | Multi-drug therapy ( N = 87) | Total ( N = 224) | ||||
| Bevacizumab (N = 19) | Ranibizumab (N = 71) | Aflibercept (N = 47) | ||||
| Eye – no (%) | ||||||
| OD | 7(37) | 33 (47) | 21 (45) | 48 (55) | 109 (49) | |
| OS | 12(63) | 38 (54) | 26 (55) | 39 (45) | 115 (51) | |
| Gender – no (%) | ||||||
| F | 16(84) | 49 (69) | 38 (81) | 58 (67) | 161 (72) | |
| M | 3(16) | 22 (31) | 9 (19) | 29 (33) | 63 (28) | |
| Race – no (%) | ||||||
| Caucasian | 12(63) | 52 (73) | 40 (85) | 72 (83) | 176 (79) | |
| African American | 2(11) | 4 (6) | 0 | 5 (6) | 11 (5) | |
| Hispanic | 3(16) | 1 (1) | 0 | 2 (2) | 6 (3) | |
| Other/Unknown | 2(11) | 14 (20) | 7 (15) | 8 (9) | 31 (14) | |
| Age | ||||||
| Mean | 78.1 12.6 | 82.1 6.5 | 83.3 6.4 | 78.2 8.7 | 80.5 8.3 | |
| 50–69 -no. (%) | 4 (21) | 2 (3) | 2 (4) | 13 (15) | 21 (9) | |
| 70–89 -no. (%) | 12 (63) | 62 (87) | 40 (85) | 66 (76) | 180 (80) | |
| 90+ -no. (%) | 3 (16) | 7 (10) | 5 (11) | 8 (9) | 23 (10) | |
| Visual Acuity (Snellen) | ||||||
| Mean | 20/94 | 20/124 | 20/91 | 20/89 | 20/100 | |
| 20/50 or Better - no. (%) | 7 (37) | 19 (27) | 20 (43) | 32 (37) | 78 (35) | |
| Between 20/50 and 20/200 - no. (%) | 7 (37) | 29 (41) | 17 (36) | 33 (38) | 86 (38) | |
| Worse than 20/200 - no. (%) | 5 (26) | 23 (32) | 10 (21) | 22 (25) | 60 (27) | |
| OCT Findings | ||||||
| SRF-no. (%) | 14 (74) | 42 (59) | 30 (64) | 73 (84) | 159 (71) | |
| IRF-no. (%) | 8 (42) | 43 (61) | 27 (57) | 28 (32) | 106 (47) | |
| OCT, optical coherence tomography; SRF, subretinal fluid; IRF, intraretinal fluid | ||||||